Jon Edwards Ph.D Overview
- Firm
- Bioqube Ventures
- Primary Position
-
Executive
- Primary Industry
-
Healthcare
- Active Board Seats
-
4
- Med. Deal Size
-
- Med. Valuation
-
Jon Edwards Ph.D General Information
Biography
Dr. Jon Edwards serves on the Board of Directors at Curebound. He served as Senior Advisor at Red Tree Venture Capital. He served as a Board Member at Rondo Therapeutics. He is a Managing Director at Red Tree Venture Capital and part of the founding investment team. Prior to joining Red Tree, he helped found Medicxi (a therapeutics-focused venture fund) where he was most recently a partner in the London office. He began his venture capital career at Index Ventures in Switzerland. Before moving to Europe, Jon was a life sciences strategy consultant at ClearView Healthcare Partners based in Boston. His investments include Synthorx (acquired by Sanofi), Phathom Pharmaceuticals (NASDAQ: PHAT), Checkmate Pharmaceuticals (NASDAQ: CMPI), Impact Biomedicines (acquired by Celgene), Sydnexis Inc., Xenikos B.V., and Breakpoint Therapeutics Gmbh. He has also held board seats on Z-Factor Ltd. (NASDAQ: CNTA), UltraHuman Ltd., and Palladio Biosciences (NASDAQ:CNTA) and was a board observer with ApcinteX Ltd. (NASDAQ: CNTA) and Capella Bioscience (NASDAQ: CNTA). He received a Ph.D. in Biochemistry and Biophysics from the University of North Carolina at Chapel Hill and holds a B.S. from the University of Vermont. He also spent time at the bench at Sepracor, Inc. and conducted his postdoctoral research at MIT. He serves as a Board Member at Sardona Therapeutics. He served as a Board Member at Excellergy Therapeutics. He also served as a Board Member at Virsti Therapeutics. He served as a Board Member at Sydnexis. He served as a Partner at Medicxi. He served as a Board member at Palladio Biosciences. He served as a Board Member at UltraHuman. Prior to Medicxi Ventures, he worked at Index as an Associate for two years. Before that, he worked as a life science strategy consultant at ClearView Healthcare Partners. He is an observer on the board of directors of Ultrahuman, Capella Bioscience, and Apcintex. He obtained his Ph.D. in biochemistry and biophysics from UNC Chapel Hill and also conducted postdoctoral research at MIT, where he is an affiliate in the Department of Biological Engineering. He also served as a Board Member at Phathom Pharmaceuticals. He serves as Board Member at Catalym. Jon recently joined the Bioqube Ventures team. Previously, he served as Managing Director at Red Tree Venture Capital and was part of the founding team at Medicxi where he was a partner in the London office. He has led multiple investments spanning company formation, syndicated deals, and late-stage crossover/IPO financings. A few notable investments include Impact Biomedicines (acquired by Celgene), Synthorx (acquired by Sanofi), Phathom Pharmaceuticals (NASDAQ:PHAT), and Checkmate Pharmaceuticals (acquired by Regeneron). Jon conducted his postdoctoral research at MIT and holds a PhD in Biochemistry and Biophysics from the University of North Carolina - Chapel Hill.
Contact Information
Address
- Barricadenplein 13
- 1000 Brussels
- Belgium
Jon Edwards Ph.D Positions (1)
Firm name | Firm type | Title | Location | Industry | Since |
---|---|---|---|---|---|
Bioqube Ventures | Investor | Executive | Brussels, Belgium | Venture Capital |
Jon Edwards Ph.D Board Seats (4)
Company | Industry | Ownership Status | Financing Status | Location | Since |
---|---|---|---|---|---|
Catalym | Drug Discovery | Privately Held (backing) | Venture Capital-Backed | Planegg, Germany | |
Curebound | San Diego, CA | ||||
Sardona Therapeutics | Discovery Tools (Healthcare) | Privately Held (backing) | Venture Capital-Backed | San Francisco, CA | |
Xenikos | Drug Discovery | Privately Held (backing) | Venture Capital-Backed | Nijmegen, Netherlands |
Jon Edwards Ph.D Lead Partner on Deals (9)
Jon Edwards Ph.D has been the lead partner on 9 deals. Their latest deal was with SynOx Therapeutics, a drug discovery company. The deal was made for on 30-Oct-2024.
Company | Deal Date | Deal Type | Deal Size | Deal Status | Industry | Location |
---|---|---|---|---|---|---|
SynOx Therapeutics | 30-Oct-2024 | Early Stage VC (Series B) | Completed | Drug Discovery | Dublin, Ireland | |
Catalym | 16-Jul-2024 | Completed | Drug Discovery | Planegg, Germany | ||
Excellergy Therapeutics | 06-Oct-2022 | Completed | Drug Discovery | Redwood City, CA | ||
Rondo Therapeutics | 22-Feb-2022 | Completed | Biotechnology | Hayward, CA | ||
Breakpoint Therapeutics | 08-Jul-2019 | Completed | Drug Discovery | Hamburg, Germany | ||
Phathom Pharmaceuticals | 15-May-2019 | Completed | Biotechnology | Florham Park, NJ | ||
Xenikos | 15-May-2018 | Completed | Drug Discovery | Nijmegen, Netherlands | ||
Palladio Biosciences | 26-Jul-2016 | Early Stage VC (Series A) | Completed | Drug Discovery | Horsham, PA | |
Sardona Therapeutics | Early Stage VC | Completed | Discovery Tools (Healthcare) | San Francisco, CA |
Jon Edwards Ph.D Network (156)
Board Members (89)
Name | Company | Representing | Location | From |
---|---|---|---|---|
Mark Stenhouse | Phathom Pharmaceuticals | Self | Florham Park, NJ | |
Colleen Cuffaro Ph.D | Catalym | Canaan Partners | Planegg, Germany | |
Curebound | Self | San Diego, CA | ||
Phathom Pharmaceuticals | Phathom Pharmaceuticals | Florham Park, NJ | ||
Catalym | BioGeneration Ventures | Planegg, Germany |
Portfolio Executives (54)
Name | Company | Role | Deal date | Location |
---|---|---|---|---|
Robert Francomano | SynOx Therapeutics | Chief Commercial Officer | 30-Oct-2024 | Dublin, Ireland |
Axel Mescheder MD | SynOx Therapeutics | Chief Medical Officer | 30-Oct-2024 | Dublin, Ireland |
SynOx Therapeutics | Chief Medical Officer | 30-Oct-2024 | Dublin, Ireland | |
SynOx Therapeutics | Chief Executive Officer & Board Member | 30-Oct-2024 | Dublin, Ireland | |
SynOx Therapeutics | Senior Vice President of Finance and Administration | 30-Oct-2024 | Dublin, Ireland |
Fund Team Members (13)
Name | Investor | Fund | Fund Location |
---|---|---|---|
Samad Wahid MD | Red Tree Venture Capital | Red Tree Venture Fund | Redwood City, CA |
Jennifer Cochran Ph.D | Red Tree Venture Capital | Red Tree Venture Fund | Redwood City, CA |
Medicxi | London, United Kingdom | ||
Medicxi | London, United Kingdom | ||
Medicxi | London, United Kingdom |
Jon Edwards Ph.D Affiliated Funds (3)
Fund | Investor | Fund Type | Status | Vintage | Size | Dry Powder | IRR | IRR Quartile |
---|---|---|---|---|---|---|---|---|
Medicxi Growth I | Medicxi | Venture - General | Closed | 2017 | ||||
Red Tree Venture Fund | Red Tree Venture Capital | Venture Capital - Early Stage | Closed | 2022 | ||||
Medicxi Ventures 1 | Medicxi | Venture - General | Closed | 2016 |
Jon Edwards Ph.D FAQs
-
Who is Jon Edwards Ph.D?
Dr. Jon Edwards serves on the Board of Directors at Curebound.
-
How much does Jon Edwards Ph.D typically invest?
Jon Edwards Ph.D's median deal size is
. -
What is Jon Edwards Ph.D’s main position?
Jon Edwards Ph.D’s primary position is Executive.
-
How many active board seats does Jon Edwards Ph.D hold?
Jon Edwards Ph.D holds 4 board seats including Catalym, Curebound, Sardona Therapeutics, and Xenikos.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read blog » -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process »